Alembic launches generic TemovateAlembic's generic Temovate provides a short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. Biosimilar drug approvals soared in 2019Ten biosimilars were approved in 2019, bringing the number of approved biosimilars to 26 since 2015. Lannett launches 2 generics Venlafaxine ER tablets, 150 mg and 225 mg, and lidocaine topical solution 4% had a market value of roughly $150 million and $17 million, respectively, for the 12 months ended November 2019. Novadoz gets FDA nod for generic Uloric The Febuxostat brand had a market value of over $430 million over the previous 12 months. Adamas settles patent litigation dispute with Sandoz Sandoz will be allowed to launch a generic version of Gocovri on March 4, 2030 or earlier under certain circumstances. Micro Labs, Mylan get FDA OK for generic Eliquis The generic is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Lannett gets FDA nod for generic butalbital, acetaminophen and caffeine capsules The two dosage strengths of BAC capsules have a combined estimated market value of approximately $68.6 million for the 12 months ended October 2019. Dr. Reddy's intros generic Nitropress The Nitropress brand and generics had a market value of approximately $8 million for the most recent 12 months ended October 2019. Lupin gets FDA OK for generic Myfortic, launches generic Hectorol Mycophenolic acid delayed-release tablets and doxercalciferol injection had a market value of roughly $174 million and $132 million, respectively. Amneal names 3 executives to its board of directors Jeff George, John Kiely and Shlomo Yanai have been appointed to Amneal’s board of directors. First Previous 168 169 170 171 172 Next Last
